| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/AAC.01750-10 |
| P953 | full work available at URL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122388 |
| P932 | PMC publication ID | 3122388 |
| P698 | PubMed publication ID | 21502632 |
| P50 | author | Nathan Paul Wiederhold | Q42104169 |
| Thomas F Patterson | Q56859142 | ||
| Laura K. Najvar | Q115923764 | ||
| Rosie A Bocanegra | Q115923770 | ||
| William R. Kirkpatrick | Q122227392 | ||
| P2860 | cites work | A drug-sensitive genetic network masks fungi from the immune system | Q21131621 |
| Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin | Q24674839 | ||
| Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment | Q28474181 | ||
| Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant | Q33722115 | ||
| In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species | Q33876423 | ||
| Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates | Q33938068 | ||
| Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients | Q33938201 | ||
| Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis | Q34006585 | ||
| Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity | Q34228214 | ||
| Anidulafungin versus fluconazole for invasive candidiasis | Q34580316 | ||
| Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy | Q34721774 | ||
| An integrated model of the recognition of Candida albicans by the innate immune system. | Q34725594 | ||
| Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. | Q34936576 | ||
| The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy | Q35185757 | ||
| Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. | Q36933000 | ||
| Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. | Q36983268 | ||
| Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility | Q37291442 | ||
| In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. | Q39077602 | ||
| The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro | Q39652699 | ||
| A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility | Q39686624 | ||
| The PKC, HOG and Ca2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans. | Q41810708 | ||
| Effects of cilofungin (LY121019) on carbohydrate and sterol composition of Candida albicans | Q42111505 | ||
| Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin | Q42119802 | ||
| Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans | Q42235292 | ||
| In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera | Q42845954 | ||
| Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies | Q43251096 | ||
| Comparison of caspofungin and amphotericin B for invasive candidiasis | Q44255071 | ||
| Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity | Q45066131 | ||
| A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. | Q46023744 | ||
| Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae | Q46577790 | ||
| Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice | Q46657418 | ||
| Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis | Q46933146 | ||
| Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient | Q46971624 | ||
| Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. | Q53596680 | ||
| Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial | Q56970523 | ||
| A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation | Q83820684 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | candidiasis | Q273510 |
| Candida albicans | Q310443 | ||
| invasive candidiasis | Q29887808 | ||
| P1104 | number of pages | 7 | |
| P304 | page(s) | 3254-3260 | |
| P577 | publication date | 2011-04-18 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans | |
| P478 | volume | 55 |
| Q61798544 | Analysis of antifungal resistance genes in Candida albicans and Candida glabrata using next generation sequencing |
| Q37544444 | Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility |
| Q38061087 | Antifungal susceptibility testing: a primer for clinicians |
| Q37394523 | CD101: a novel long-acting echinocandin |
| Q41833091 | Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints |
| Q35806170 | Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata |
| Q34977071 | Composite survival index to compare virulence changes in azole-resistant Aspergillus fumigatus clinical isolates |
| Q35941237 | Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations |
| Q36276186 | Echinocandin Resistance in Candida |
| Q38988521 | Echinocandin Resistance in Candida Species: a Review of Recent Developments |
| Q38027469 | Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. |
| Q38254290 | Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management |
| Q42638073 | Effects of Echinocandins in Combination with Nikkomycin Z against Invasive Candida albicans Bloodstream Isolates and the fks Mutants |
| Q91865119 | Efficacy of humanized single large doses of caspofungin on the lethality and fungal tissue burden in a deeply neutropenic murine model against Candida albicans and Candida dubliniensis |
| Q35666505 | Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo |
| Q34298898 | In vitro analysis of finasteride activity against Candida albicans urinary biofilm formation and filamentation |
| Q35173939 | Matrine reduces yeast-to-hypha transition and resistance of a fluconazole-resistant strain of Candida albicans |
| Q38266675 | Mechanisms of Antifungal Drug Resistance |
| Q38550402 | Mechanisms of echinocandin antifungal drug resistance |
| Q40040802 | Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment. |
| Q47410811 | Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata |
| Q38919690 | Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality. |
| Q33798606 | Positions and numbers of FKS mutations in Candida albicans selectively influence in vitro and in vivo susceptibilities to echinocandin treatment. |
| Q91292102 | Rhesus Theta Defensin 1 Promotes Long Term Survival in Systemic Candidiasis by Host Directed Mechanisms |
| Q58037544 | Surface coatings with covalently attached caspofungin are effective in eliminating fungal pathogens |
| Q38095809 | The evolving role of antifungal susceptibility testing |
| Q34923233 | The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans |
| Q35105818 | The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans. |
| Q27026751 | The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida |
| Q41135029 | Update on Antifungal Drug Resistance |
Search more.